EU Biotech Campus and Univercells announce strategic collaboration. 

Univercells’ mRNA manufacturing technology at the EU Biotech Campus site to serve as a hands-on training tool, simulating real-life biotech industry scenarios. 

Dedicated Academy with high-tech trainings for all Univercells collaborators, international business partners, student, job seekers as well as projects initiated in low- and middle-income countries (LMICs). 

Long-term partnership aimed to serve biotech and pharma companies finding skilled people in Belgium and abroad. 

Gosselies, Belgium – February 9, 2024 – EU Biotech Campus, a new state-of-the-art and multi-operator training center for the health & biotech sector, and Univercells, a global life sciences player, are delighted to announce a long-term training collaboration. This partnership aims to provide a dynamic learning environment for Belgian and international students and professionals while developing cutting-edge expertise to meet the evolving needs of the fast-growing life sciences industry. 

Univercells brings together various biotech affiliates, covering the entire healthcare value chain and working together to make biologics available to all. The company leverages strengths in scaling and industrialization, bioproduction, and bioprocessing to find new ways to support access to medicines and promote sustainability. 

Located in the Brussels South Charleroi Biopark (Belgium), the EU Biotech Campus provides specialized courses tailored to industry needs and trains students and professionals in next generation biomanufacturing technologies. The Campus – currently under construction – will soon launch its first pilot training programs focused on 4.0 skills for biomanufacturing, maintenance and supply chains activities. 

mRNA Production Reinvented 

Under this agreement, Univercells will provide its mRNA manufacturing technology at the EU Biotech Campus, which will serve as a practical training tool, simulating real-world biotech industry scenarios and allowing trainees (collaborators, customers, students, job seekers) hands-on experience. 

Developed by Quantoom Biosciences – part of Univercells -, this technology called Ntensify™ is a game-changer for the development and production of mRNA-based medicines. Supported by the Bill & Melinda Gates Foundation, Quantoom Biosciences has developed a full line of Ntensify™products fitting very-small to very-large scale production capacities to accelerate mRNA vaccine innovation and distributed manufacturing in low-and middle-income countries (LMICs). 

The EU Biotech Campus will develop customized training programs for Univercells collaborators, focusing on next generation biomanufacturing processes and advanced 4.0skills, providing trainees with state-of-the-art machinery, tools and technologies used in the biotech sector. 

Hugues BultotCo-Founder and Chief Executive Officer of Univercells, commented: Seeing the construction of the EU Biotech Campus where Univercell’s activities originally began, in Gosselies, is very stimulating. Wallonia is a renowned biotech Hub. Adding cutting-edge trainings to its offer will bring additional exposure to the Region from a different angle. We know how critical it is to find skilled people and to stay up to date in the life sciences sector. Offering professional trainings to young or unemployed people will increase their hiring potential and serve biotech and pharma companies looking for talented individuals in Belgium and abroad. We are excited to be part of this project and we look forward to seeing the campus opening its doors next year.”

Frédéric Druck, Chairman EU Biotech Campus, commented: « We are very excited to announce this partnership with Univercells which is first in a long series to come and to combine our expertise to offer leading-edge training programs, for both Belgian and international students and professionals. We are extremely proud that the EU Biotech Campus can showcase such technology, invented, developed, and produced in Belgium. Together, we look forward to driving innovation, fostering talent development, and contributing to the continued success and growth of the life sciences sector._” _


 Contacts Media

EU Biotech Campus
Maud Vanderthommen 
Communication Manager essenscia
+32 473 58 61 04
Cécile Hisette
VP Corporate Communications 
+32 473.36.14.11 

About Univercells 

Univercells is a global life sciences company with the mission of making biologics accessible to all. Using our combined expertise in scaling, production and bioprocessing, Univercells finds new and sustainable ways to widen access to life-changing drugs. Our affiliate companies deploy innovations in infrastructure, drug substance manufacturing, equipment manufacturing, equipment design, training, and on-the-ground health services to drive down costs, shrink manufacturing footprints and meet the needs of the entire health value chain. Headquartered in Jumet (Belgium), Univercells is supported by regional and national investors, as well as international investors active in vaccines and healthcare, such as the European Investment Bank and Global Health Investment Fund, among others. 

About EU Biotech Campus 

The EU Biotech Campus is a brand-new multi-operator training center dedicated to developing talents for the fast-growing health & biotech industry. It offers state-of-the-art infrastructure and tailored training programs for students, academics, and industry. The EU Biotech Campus aims to train people in next generation biomanufacturing technologies, including automation, digitalization, miniaturization, bioprocesses for the production of advanced therapeutical medicine, vaccines and diagnostics. The Campus offers training labs, innovative training rooms, a STEM immersion showroom, 1 auditorium and 1 online matching platform. It is located in the Biopark in Gosselies (Belgium), a unique integrated biotech close to Brussels South Charleroi airport and will be fully operational in the second half of 2025. The EU Biotech Campus is one of the most strategic investments of the Belgian Recovery and Resilience Plan, approved by the European Commission in July 2021.